Physician profile
Jyotsna Talapaneni
NPI 1720116494
$12,280.03
in general payments reported to CMS, 2019-2025
42 companies · $2,633 in 2025
The $2,633 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $628 · 2021: $1,311 · 2022: $1,947 · 2023: $2,060 · 2024: $2,821 · 2025: $2,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,499 · Education: $15.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,498.68 |
| Education | $15.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,021.15 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,327.12 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,099.47 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $931.02 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $650.85 | 2019-2025 | |
| Gilead Sciences, INC. | $507.72 | 2019-2025 | Livdelzi |
| Ardelyx, INC. | $499.61 | 2023-2025 | Ibsrela |
| Celgene Corporation | $478.07 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $402.14 | 2023-2025 | Dupixent |
| Genzyme Corporation | $378.85 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $302.46 | 2020-2025 | Ocaliva |
| Qol Medical, LLC | $226.42 | 2023-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $224.63 | 2020-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $201.62 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $181.01 | 2020-2023 | Linzess |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $180.11 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $167.94 | 2021-2022 | |
| Lilly USA, LLC | $160.57 | 2024 | Omvoh, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $134.34 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $132.66 | 2024-2025 | Iqirvo, Bylvay |
| Madrigal Pharmaceuticals | $121.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $91.61 | 2023-2024 | Renflexis, Hadlima |
| Celltrion USA INC. | $91.03 | 2023-2025 | Vegzelma, Yuflyma |
| Intra-Sana Laboratories | $78.70 | 2021-2022 | |
| Evoke Pharma, INC. | $72.72 | 2021-2024 | |
| Alfasigma USA, INC. | $56.65 | 2020 | |
| Vivus LLC | $54.07 | 2021-2025 | Qsymia |
| Amgen INC. | $51.55 | 2023-2025 | Amjevita, Avsola, Uplizna |
| Redhill Biopharma INC. | $50.24 | 2023 | Talicia, Aemcolo |
| Ucb, INC. | $44.66 | 2019 | |
| Mallinckrodt Hospital Products INC. | $42.73 | 2025 | Terlivaz |
| Ferring Pharmaceuticals INC. | $42.06 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $40.22 | 2024 | |
| Sandoz INC. | $37.82 | 2024-2025 | Hyrimoz |
| Daiichi Sankyo INC. | $37.14 | 2020-2021 | |
| Shionogi INC | $33.29 | 2019 | |
| Merit Medical Systems INC | $25.89 | 2025 | Big60 Inflation Device, Esophyx |
| Vbi Vaccine (Delaware) INC. | $25.50 | 2022 | |
| Biocompatibles, INC. | $22.78 | 2019 | |
| Endo Pharmaceuticals INC. | $20.10 | 2019 | |
| Stryker Corporation | $18.40 | 2024 | Surgicount |
| Endogastric Solutions, INC | $13.75 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyotsna Talapaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.